News

The U.S. Patent and Trademark Office (USPTO) has granted Conduit Pharmaceuticals a patent for AZD1656, its experimental therapy for ANCA-associated vasculitis (AAV) and other autoimmune diseases. The USPTO granted a composition of matter patent, which is a type of patent that relates to novel compounds made from two or…

Long-term treatment with Nucala (mepolizumab) — approved for use in EGPA, or eosinophilic granulomatosis with polyangiitis, the rarest type of ANCA-associated vasculitis — appears to be well tolerated by most patients, and was seen to reduce or even eliminate corticosteroid use. That’s according to new data from an…

Adding Tavneos (avacopan) to standard treatment is as safe and effective in older people with ANCA-associated vasculitis (AAV) as it is among younger patients, according to the findings of a post-hoc analysis of clinical trial data. The approved oral therapy “showed similar efficacy and safety results in patients…

Disease symptoms among people with ANCA-associated vasculitis (AAV) were found to vary by age at diagnosis and biological sex, according to data from more than 1,100 Scandinavian patients. “We identified significant differences in clinical presentation of the disease between female and male patients and between patients with a young…

A Phase 1 clinical trial assessing SC291, an experimental CAR T-cell therapy that Sana Biotechnology is developing for ANCA-associated vasculitis (AAV) and other autoimmune diseases, is recruiting patients at a number of sites across the U.S. Called GLEAM (NCT06294236), the study started enrolling up to…

A higher risk of death among AAV patients with interstitial lung disease (ILD) is significantly associated with older age, episodes of sudden symptom worsening, and microscopic polyangiitis (MPA), a common type of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). That’s according to a review of published studies that also pointed…

Researchers have identified new contributors to the abnormal immune responses against the myeloperoxidase (MPO) enzyme that drive ANCA-associated vasculitis (AAV) in some patients. Specifically, these abnormal responses are marked by high numbers of memory B-cells that produce an antibody type called immunoglobulin M (IgM). Memory B-cells are immune cells crucial to…

The frequency of ANCA-associated vasculitis (AAV) among the Indigenous peoples of Alaska is high compared with other populations worldwide, especially the granulomatosis with polyangiitis (GPA) form of the disease,  a study reports. Native Alaskans and American Indians in Alaska with AAV also may have more severe clinical features at…

Lower blood levels of glutathione peroxidase-3 (GPX-3), an antioxidant enzyme, are significantly associated with greater disease activity and blood vessel damage in people with ANCA-associated vasculitis (AAV), a study found. “We demonstrated that [blood] GPX-3 concentration at diagnosis has the potential to be a novel biomarker that can assess…

Long-term treatment with Nucala (mepolizumab) reduces disease activity and helps to prevent progressive organ damage in people with eosinophilic granulomatosis with polyangiitis (EGPA), the rarest type of ANCA-associated vasculitis (AAV), data from a real-world study show. Finding among patients in Spain also showed that most using Nucala were able…